Iambic Therapeutics Inc

10/19/2026 | Press release | Distributed by Public on 10/19/2026 18:20

Statement of Changes in Beneficial Ownership (Form 4)

FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden hours per response... 0.5
(Print or Type Responses)
1. Name and Address of Reporting Person *
Catalio Capital Management, LP
2. Issuer Name and Ticker or Trading Symbol
Iambic Therapeutics, Inc. [IAM]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director __X__ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
(Last) (First) (Middle)
512 W. 22ND STREET, 5TH FLOOR
3. Date of Earliest Transaction (Month/Day/Year)
10/16/2026
(Street)
NEW YORK, NY 10011
4. If Amendment, Date Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
___ Form filed by One Reporting Person
_X_ Form filed by More than One Reporting Person
(City) (State) (Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)
7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/16/2026 C 1,995,749 A (1)(2)(3) 1,995,749 I See footnote(4)
Common Stock 10/16/2026 C 1,458,290 A (5) 1,458,290 I See footnote(6)
Common Stock 10/16/2026 C 742,546 A (7) 742,546 I See footnote(8)
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)
6. Date Exercisable and Expiration Date
(Month/Day/Year)
7. Title and Amount of Underlying Securities
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)
11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Series A Convertible Preferred Stock (1) 10/16/2026 C 1,141,878 (1) (1) Common Stock 1,141,878 $ 0 0 I See foonote(4)
Series B Convertible Preferred Stock (2) 10/16/2026 C 731,187 (2) (2) Common Stock 731,187 $ 0 0 I See footnote(4)
Series B-3 Convertible Preferred Stock (3) 10/16/2026 C 122,684 (3) (3) Common Stock 122,684 $ 0 0 I See footnote(4)
Series B-4 Convertible Preferred Stock (5) 10/16/2026 C 1,458,290 (5) (5) Common Stock 1,458,290 $ 0 0 I See footnote(6)
Convertible Promissory Notes (7) 10/16/2026 C 742,546 10/16/2026 08/14/2028 Common Stock 742,546 $ 0 0 I See footnote(8)

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Catalio Capital Management, LP
512 W. 22ND STREET
5TH FLOOR
NEW YORK, NY 10011
X
Catalio Nexus Fund III, LP
512 W. 22ND STREET
5TH FLOOR
NEW YORK, NY 10011
X
Catalio Access Fund VIII, LLC
512 W. 22ND STREET
5TH FLOOR
NEW YORK, NY 10011
X
Catalio BH SPV, LLC
512 W. 22ND STREET, 5TH FLOOR
NEW YORK, NY 10011
X
Petrocheilos George C
512 W. 22ND STREET
5TH FLOOR
NEW YORK, NY 10011
X

Signatures

/s/ Olga Maltseva, Chief Compliance Officer of Catalio Capital Management, LP 10/19/2026
**Signature of Reporting Person Date
/s/ Olga Maltseva, Chief Compliance Officer of Catalio Capital Management, LP, Manager of Catalio Nexus Fund III, LP 10/19/2026
**Signature of Reporting Person Date
/s/ Olga Maltseva, Chief Compliance Officer of Catalio Capital Management, LP, Manager of Catalio Access Fund VIII, LLC 10/19/2026
**Signature of Reporting Person Date
/s/ Olga Maltseva, Chief Compliance Officer of Catalio Capital Management, LP, Manager of Catalio Access Fund VIII, LLC 10/19/2026
**Signature of Reporting Person Date
/s/ George C. Petrocheilos, individually 10/19/2026
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.
(2) Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.
(3) Each share of Series B-3 Convertible Preferred Stock automatically converted into Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.
(4) The shares are held of record by Catalio Nexus Fund III, LP, or Catalio Nexus. Catalio Capital Management, LP, or Catalio Capital Mgmt, a registered investment adviser, is the investment manager for Catalio Nexus. R. Jacob Vogelstein and George C. Petrocheilos are managing partners of Catalio Capital Mgmt. Messrs. Vogelstein and Petrocheilos share voting and dispositive power with respect to the shares held by Catalio Nexus. Catalio Capital Mgmt, Mr. Vogelstein and Mr. Petrocheilos each disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein, if any.
(5) Each share of Series B-4 Convertible Preferred Stock automatically converted into Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.
(6) The shares are held of record by Catalio Access Fund VIII, LLC, or Catalio Access. Catalio Capital Mgmt provides investment management services for Catalio Access. R. Jacob Vogelstein and George C. Petrocheilos are managing partners of Catalio Capital Mgmt. Messrs. Vogelstein and Petrocheilos share voting and dispositive power with respect to the shares held by Catalio Access. Catalio Capital Mgmt, Mr. Voglestein and Mr. Petrocheilos each disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein, if any.
(7) The conversion price was equal to 85% of the Issuer's initial public offering price of $16.00 per share (reflecting a 15% discount).
(8) The shares are held of record by Catalio BH SPV, LLC, or Catalio SPV. Catalio Capital Mgmt is the investment manager for Catalio SPV. R. Jacob Vogelstein and George C. Petrocheilos are managing partners of Catalio Capital Mgmt. Messrs. Vogelstein and Petrocheilos share voting and dispositive power with respect to the shares held by Catalio SPV. Catalio Capital Mgmt, Mr. Vogelstein and Mr. Petrocheilos each disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein, if any.

Remarks:
The Reporting Persons' beneficial ownership has fallen below ten percent. As a result, the Reporting Persons are no longer subject to Section 16 in connection with its transactions in the equity securities of the Issuer and therefore will no longer report any such transactions on Form 4 or Form 5.
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.
Iambic Therapeutics Inc published this content on October 19, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on October 20, 2026 at 00:20 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]